FDA Brief

Warning letters Food

FDA warning letter to

Proper Nutrition Inc.

LowIssued Apr 20, 2021Posted Apr 27, 2021Human and Animal Food Division II East

FDA warned Proper Nutrition that website claims made its colostrum and peptide supplements unapproved new drugs and misbranded.

What happened

In April 2021, FDA reviewed propernutrition.com and found order pages and claims that the products are intended to cure, mitigate, treat, or prevent disease. FDA cited claims about wound healing, Crohn's, IBS, infection, and digestive disorders. Because the products are not generally recognized as safe and effective for these uses and lack FDA approval, FDA called them new drugs; Seacure and SeaVive also lacked adequate directions for lay use.

What FDA found

  1. Website claims that the products treat or prevent disease make them drugs under the law.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
  2. FDA says the products are new drugs—not generally recognized as safe and effective for their claimed uses—and need FDA approval before sale.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  3. Seacure and SeaVive are intended for diseases a layperson cannot safely self-treat, so they are misbranded—lacking adequate directions for safe lay use.

    FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. The letter says selling these misbranded drugs in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks Proper Nutrition to notify it in writing within 15 working days of receipt about the specific steps taken to address the violations, including how it will prevent recurrence and related documents; if the company disagrees, it should include its reasoning and supporting information. If corrections cannot be completed in that time, the company must state why and give a completion date.

Who should pay attention

  • dietary supplement companies making disease-treatment claims
  • retailers and distributors selling supplement products with drug-like claims
  • firms marketing colostrum or peptide supplements online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk